Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Duerschmied

Showing results (1-10 of 254) with videos related to

Pageof 26
Sort By:
Hamostaseologie|December 1, 2018
Proceedings of the Third Freiburg Thrombosis MeetingDaniel Duerschmied
Thrombosis and Haemostasis|July 31, 2018
Life-Saving Therapy versus Symptom Relief: Anti-Platelet Agents and Opioids in Coronary InterventionDaniel Duerschmied, Christoph Bode
Cardiovascular Research|April 22, 2016
Hsp70 preventing thrombosis: benefit without burden?Daniel Duerschmied, Christoph Bode
Journal of Thrombosis and Thrombolysis|May 13, 2021
ICODE: the international COVID-19 thrombosis biomarkers colloquium-novel soluble biomarkers: circulating cell-free nucleic acids and other moleculesKrystin Krauel, Daniel Duerschmied
Journal of Critical Care|August 21, 2021
Does adjunctive hemoadsorption with CytoSorb affect survival of COVID-19 patients on ECMO? Authors' responseAlexander Supady, Daniel Duerschmied
The New England Journal of Medicine|April 21, 2021
Cytokine StormAlexander Supady, Christoph Bode, Daniel Duerschmied
Thrombosis and Haemostasis|September 12, 2014
Immune functions of plateletsDaniel Duerschmied, Christoph Bode, Ingo Ahrens
Expert Review of Cardiovascular Therapy|September 11, 2010
Clopidogrel in acute coronary syndrome: implications of recent study findingsDaniel Duerschmied, Christoph Bode, Martin Moser
Therapeutics and Clinical Risk Management|September 9, 2015
Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosisPhilipp Diehl, Christoph Bode, Daniel Duerschmied
Frontiers in Cardiovascular Medicine|August 5, 2017
The Effects of Serotonin in Immune CellsNadine Herr, Christoph Bode, Daniel Duerschmied
Pageof 26

Showing results (1-10 of 254) with videos related to

Sort By:
Pageof 26
Hamostaseologie|December 1, 2018
Proceedings of the Third Freiburg Thrombosis MeetingDaniel Duerschmied
Thrombosis and Haemostasis|July 31, 2018
Life-Saving Therapy versus Symptom Relief: Anti-Platelet Agents and Opioids in Coronary InterventionDaniel Duerschmied, Christoph Bode
Cardiovascular Research|April 22, 2016
Hsp70 preventing thrombosis: benefit without burden?Daniel Duerschmied, Christoph Bode
Journal of Thrombosis and Thrombolysis|May 13, 2021
ICODE: the international COVID-19 thrombosis biomarkers colloquium-novel soluble biomarkers: circulating cell-free nucleic acids and other moleculesKrystin Krauel, Daniel Duerschmied
Journal of Critical Care|August 21, 2021
Does adjunctive hemoadsorption with CytoSorb affect survival of COVID-19 patients on ECMO? Authors' responseAlexander Supady, Daniel Duerschmied
The New England Journal of Medicine|April 21, 2021
Cytokine StormAlexander Supady, Christoph Bode, Daniel Duerschmied
Thrombosis and Haemostasis|September 12, 2014
Immune functions of plateletsDaniel Duerschmied, Christoph Bode, Ingo Ahrens
Expert Review of Cardiovascular Therapy|September 11, 2010
Clopidogrel in acute coronary syndrome: implications of recent study findingsDaniel Duerschmied, Christoph Bode, Martin Moser
Therapeutics and Clinical Risk Management|September 9, 2015
Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosisPhilipp Diehl, Christoph Bode, Daniel Duerschmied
Frontiers in Cardiovascular Medicine|August 5, 2017
The Effects of Serotonin in Immune CellsNadine Herr, Christoph Bode, Daniel Duerschmied
Pageof 26